NEW YORK, April 23 (Reuters) - Becton Dickinson and Co BDX.N will acquire C R Bard Inc BCR.N in a $24 billion deal that will give shareholders of the target about 15 percent of the combined entity, the two medical technology companies said on Sunday.
The "definitive" cash and stock agreement, which has been approved by directors of both companies, values Bard shares at $317.00 each.